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Most adenovirus transducing vectors have the cytomegalovirus major immediate-early (CMV) or the Rous sarcoma virus
long terminal repeat (RSV) promoter driving expression of the transgene. Both of these promoters are highly active in
transfection and transduction assays in 293 cells, in which transducing vectors are constructed and grown, and in HeLa cells.
The CMV promoter exhibits rapid activation while the RSV promoter exhibits a lag prior to the onset of viral DNA replication
in transduction assays. While the use of very strong promoters facilitates expression of the transgene, high-level expression
of certain gene products hinders virus construction and growth. For such genes, the use of the adenovirus type 5 E1A
promoter offers advantages. The E1A promoter exhibits modest activity in HeLa cells after transfection or transduction, but
very little activity in 293 cells, suggesting that the E1A promoter would permit construction and growth of vectors encoding
deleterious gene products that could not be constructed with the CMV and RSV promoters. This idea was tested through
attempts to construct viruses encoding the immunoglobulin loop 6 and transmembrane regions of the prostaglandin F2a
receptor regulatory protein (FPRP), a product that inhibits adenovirus vector construction for reasons that are not clear. Only
the E1A promoter permitted construction and growth of the transducing vector encoding the fragment of FPRP. © 2001 Elsevier
Science
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Recombinant adenovirus vectors are widely used for
transducing cells both in vitro and in vivo. Numerous
systems for construction of recombinant adenoviruses
have been developed (Bett et al., 1994; Chartier et al.,
1996; Crouzet et al., 1997; Graham et al., 1989; Hardy et
al., 1997; He et al., 1998; Ketner et al., 1994; Mitani et al.,
1995; Mizuguchi and Kay, 1998; Schaack et al., 1995),
most of which are designed to incorporate the highly
active cytomegalovirus promoter to direct expression of
the introduced gene. Aside from the CMV promoter, the
Rous sarcoma virus long terminal repeat (RSV) promoter,
which also directs high-level expression in a broad
range of tissues and cells, is frequently used in adeno-
virus transducing vectors. While the CMV and RSV pro-
moters are generally strong, both promoters exhibit tis-
sue specificity in their activities (Smith et al., 2000).
For many studies, extremely high-level expression of
the gene of interest is desired and the use of the CMV or
RSV promoter is appropriate. However, transducing vi-
ruses that direct synthesis of lower levels of proteins or
1 To whom correspondence and reprint requests should be ad-
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101direct expression in a regulated manner are necessary
in certain cases. The utility of promoters that either direct
expression in a tissue-specific manner (Fukuchi et al.,
1994; Hashimoto et al., 1996; Imler et al., 1996) or re-
spond to specific conditions (Varley et al., 1995) has been
demonstrated. The strength of promoters that exhibit
broad specificity has been examined using adenovirus
transducing vectors (Ambriovic et al., 1997; Castro et al.,
1997; Elshami et al., 1997; Guo et al., 1996; Sallenave et
al., 1998; Xu et al., 1995). Among weaker promoters that
exhibit broad tissue specificity, the E1A promoter has
been successfully used (Fagan et al., 1999; Jiang et al.,
1996; Staley et al., 1996).
The goal of this study was to examine the utility of the
E1A promoter in the construction of adenovirus trans-
ducing vectors encoding a gene product deleterious to
construction and/or growth of the virus. The kinetics of
expression of the reporter gene GFP under the control of
the CMV, RSV, and E1A promoters was examined during
transfection as a means to mimic steps in the construc-
tion of a recombinant virus and during transduction of
293 and HeLa cells. The E1A promoter within the context
of the viral chromosome is inhibited in 293 cells. This
finding led to the hypothesis that the E1A promoter could
be used in a simple expression system to construct
viruses encoding deleterious gene products. This hy-
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102 SCHAACK ET AL.pothesis was tested using a cDNA encoding the immu-
noglobulin loop 6 and transmembrane regions of the
prostaglandin F2a receptor regulatory protein (FPRP; Or-
licky and Nordeen, 1996) and found to be correct.
RESULTS
The viral E1A promoter exhibits little activity during
the early phase of infection of 293 cells
293 and HeLa suspension cells were infected at an
m.o.i. of 25 PFU/cell with the phenotypically wild-type
virus Ad5dl310 (Jones and Shenk, 1979b). Ad5dl310 con-
tains an in-frame deletion of 27 bp that encompasses the
FIG. 1. Synthesis of E1A mRNA in cells infected with Ad5dl310.
Cytoplasmic RNA isolated from 293 and HeLa suspension cells 5 h
after infection with Ad5dl310 was analyzed by RNase protection using
a uniformly 32P-labeled antisense probe that overlaps the full length of
the E1A mRNAs. The antisense probe and the E1A 13S and 12S mRNAs
are schematically represented at the top. Protection products were
isolated by electrophoresis on a polyacrylamide gel. Ad5dl310 has a
27-bp deletion in the region encoding the 39 exon of E1A such that the
virus is phenotypically wild-type but E1A mRNAs arising from the E1A
gene within 293 cells and the viral E1A gene can be distinguished.
Protected species are indicated.
FIG. 2. Recombinant adenoviruses. Replication-defective transducin
promoters in place of the E1 region were constructed by overlap
chromosome is schematically represented as a horizontal line, with early r
indicates the deletion within the E3 region. The region of insertion of the repXbaI site at 1340 bp, so the 39 exon of E1A mRNAs
arising from this virus is readily discernible in an RNase
protection assay from the 39 exon from the E1A mRNA of
293 cells (Hearing and Shenk, 1985). Analysis of the E1A
mRNA present 5 h after infection demonstrated little
virus-specific E1A mRNA in 293 cells in contrast to a
substantial amount of E1A mRNA in HeLa cells (Fig. 1).
Other viruses with E1A mRNA distinguishable from 293
E1A mRNA also exhibited reduced amounts of virus-
specific E1A mRNA in 293 cells relative to HeLa cells
(data not shown). In comparison, E2A mRNA was re-
duced less than twofold in 293 cells relative to HeLa
cells 5 h after infection (data not shown).
The inefficient synthesis of viral E1A mRNA during the
early phase of infection suggests that the high level of
E1A protein constitutively present in 293 cells represses
the viral E1A promoter (Smith et al., 1985) or that it
prevents activation of the viral E1A promoter. Reduced
activity of the E1A promoter in 293 cells offers potential
utility in the design of adenovirus vectors for expression
of foreign products that are deleterious to 293 cells or in
construction and growth of the virus, as foreign genes
whose expression is directed by the E1A promoter
should be down-regulated in 293 cells relative to other
promoters. The activity of the E1A promoter was further
examined relative to other promoters commonly used in
adenovirus transducing vectors.
Relative promoter activities in transfected and
transduced 293 cells
The activities of the CMV, E1A, and RSV promoters in
293 cells were indirectly examined by analysis of fluo-
rescence after transfection with plasmids encoding GFP
and after transduction with viruses encoding GFP (Fig.
2). Fluorescence was maximal near 48 h after transfec-
tion for all three promoters (Fig. 3A). The activity of the
CMV promoter, which is activated by the E1A 289R pro-
tein (Gorman et al., 1989), was greater than that of the
RSV promoter and much greater than that of the E1A
promoter.
In transduced 293 cells, the activity of the CMV pro-
moter was again greater than that of the RSV promoter
(Fig. 3B). However, the kinetics of expression suggests
oviruses encoding GFP under the control of the CMV, E1A, and RSV
ination as outlined under Materials and Methods. The adenovirusg aden
recombegion genes indicated by arrows above. A thickened horizontal line
orter cassettes is indicated by dashed lines.
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promoters lies in the rate of activation and not in the
FIG. 3. GFP activity in 293 cells. (A) Transfected cells. (B) Transduced
cells. (C) Relative concentration of Ad DNA present in transduced cells.
At times indicated after transfection (A) or transduction (B), cells were
harvested and GFP activity was determined. Fluorescence is plotted as
a function of time. The relative concentration of Ad5dl327RSV–GFP
DNA present within transduced cells was determined by slot blot and
is presented (C).maximal activity. The RSV promoter exhibited activity
similar to that of the E1A promoter 6 h after transduction,but became highly active by 12 h after transduction. The
rate of increase in fluorescence directed by the CMV and
RSV promoters was approximately parallel after 12 h. It is
possible that 293 cells support a greater number of
active RSV promoters than active CMV promoters. Alter-
natively, since viral DNA replication initiated between 6
and 12 h after infection (Fig. 3C; all viruses replicated
similarly; data for only Ad5dl327RSV–GFP are pre-
sented), it is possible that the RSV promoter is activated
by replication.
Relative promoter activities in transfected and
infected HeLa cells
The activities of the CMV, E1A, and RSV promoters
were compared after transfection of HeLa cells (Fig. 4A).
The fluorescent signals in HeLa cells were much lower
than those in 293 cells (compare Figs. 3A and 4A). The
efficiency of transfection of 293 cells is much higher than
that of HeLa cells, at least in part due to stabilization of
transfected DNA in 293 cells (Alwine, 1985). As in 293
cells, peak fluorescence was apparent near 48 h after
transfection and the CMV promoter was the most active.
However, the RSV promoter was nearly as active as the
CMV promoter and the activity of the E1A promoter was
much closer to that of the CMV and RSV promoters than
in 293 cells.
In transduced HeLa cells, the CMV promoter was
again the most active and the RSV promoter exhibited a
substantial lag prior to high-level activation (Fig. 4B). The
activity of the E1A promoter was quite similar to that of
both the RSV promoter through 24 h after transduction
and the E1A promoter during the early phase in 293 cells.
The reduced activity of the E1A promoter in HeLa cells
transduced with the GFP-encoding virus relative to HeLa
cells infected with the wild-type virus (compare Fig. 4B
with Fig. 1) is due to the lack of transcriptional activation
of the E1A promoter driving GFP expression (Jones and
Shenk, 1979a; Berk et al., 1979).
Replication of viral DNA from the GFP-encoding vi-
ruses is less efficient and exhibits a longer lag in HeLa
cells than in 293 cells due to lack of complementation
for the E1 genes in HeLa cells (Shenk et al., 1979).
Viral DNA replication in HeLa cells began between 12
and 24 h after transduction and continued throughout
the course of the analysis (Fig. 4C; again, data for only
Ad5dl327RSV–GFP are presented). However, substan-
tially less replication occurred in HeLa cells than in 293
cells. The increased activity of the RSV promoter after the
onset of viral DNA replication suggests that the activity of
the RSV promoter is also dependent on replication of
viral DNA in HeLa cells.
Test of the E1A promoter for virus constructionExpression of FPRP rises dramatically after induction
of differentiation of 3T3 L1 cells into adipocytes (Orlicky
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FIG. 4. GFP activity in HeLa cells. (A) Transfected cells. (B) Trans-
duced cells. (C) Relative concentration of Ad DNA present in trans-
duced cells. At times indicated after transfection (A) or transduction (B),
cells were harvested and GFP activity was determined. Fluorescence is
plotted as a function of time. The relative concentration of
Ad5dl327RSV–GFP DNA present within transduced cells was deter-
mined by slot blot and is presented (C).entiation and function are under study. Using the AdEasy
system (He et al., 1998), we have constructed adenovirustransducing vectors encoding the wild-type as well as
various mutant alleles of FPRP under the control of the
CMV promoter (Orlicky and Schaack, unpublished re-
sults). However, it proved difficult to construct a virus
encoding only the immunoglobulin loop 6 and transmem-
brane (Ig6/TM) regions of FPRP (see Orlicky and Nor-
deen, 1996, for the proposed structure of FPRP). Twenty-
four independent transfections of the Ad chromosome
encoding FPRP Ig6/TM under the control of the CMV
promoter and GFP under a second CMV promoter led to
the formation of two plaques, both fluorescent. Sequence
analysis of the viral DNAs from the plaques demon-
strated that, while the GFP gene and its CMV promoter
were present, the FPRP cDNA fragment and its CMV
promoter had been deleted (data not shown), presum-
ably through recombination between the CMV promot-
ers. In addition, attempts to construct the virus using
overlap recombination or ligation (a method that we have
found to be most efficient; Fagan et al., 1999) with
Ad5dl327Bstb-gal-TP were unsuccessful. The repeated
failure to construct a virus encoding FPRP Ig6/TM under
the control of the CMV promoter suggests that high-level
expression of FPRP Ig6/TM is deleterious to the virus
and/or the cells.
The RSV promoter exhibits a lag prior to full activity
that occurs after the onset of viral DNA replication (Figs.
3B, 3C, 4B, and 4C). This raised the possibility that an
adenovirus transducing vector encoding FPRP Ig6/TM
expression under the control of the RSV promoter could
be constructed. The fused FPRP Ig6/TM–GFP cDNA was
cloned into the plasmid pShuttleRSV and then introduced
into pAdEasy1 (see Materials and Methods). Eight inde-
pendent transfections of 293 cells led to the production
of a single plaque that was apparent only after 2 weeks
of incubation. The virus from the plaque was used to
infect new 293 cells. Development of CPE and increased
fluorescence progressed very slowly. After successive
passages, the virus began to grow more rapidly, concom-
itant with loss of fluorescence. Sequence analysis of the
rapidly growing viral DNA demonstrated that a frameshift
mutation had occurred, eliminating expression of FPRP
Ig6/TM as well as GFP (data not shown). This evidence
suggests that a virus encoding FPRP Ig6/TM under the
control of the RSV promoter had been constructed, but
that growth of this virus was extremely inefficient. Only
when a spontaneous mutant, in which FPRP Ig6/TM
expression was lost, arose did efficient viral growth oc-
cur.
Finally, an attempt was made to construct a transduc-
ing vector in which the E1A promoter controlled expres-
sion of the FPRP Ig6/TM–GFP cDNA. For this purpose,
both overlap recombination with Ad5dl327Bstb-gal-TP
complex and the AdEasy system were used (see Mate-
rials and Methods). Immunoprecipitation (Fig. 5), fluores-
cence, PCR, and sequence (data not shown) analyses
demonstrated the presence of the gene within recombi-
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cells, confirming the hypothesis that use of the E1A
promoter would permit construction and growth of ade-
novirus transducing vectors that could not be con-
structed and grown using the CMV or RSV promoters.
DISCUSSION
Most of the adenovirus transducing vectors con-
structed to date use either the RSV or the CMV promoter
to drive expression of the transduced gene. Both of these
promoters are strong. However, extremely high-level ex-
pression of certain gene products in transduced cells
may be neither required (Fagan et al., 1999; Jiang et al.,
1996; Staley et al., 1996) nor desirable and may be del-
eterious (Larregina et al., 1998) in the construction or
growth of the virus.
Adenovirus transducing vectors encoding gene prod-
ucts deleterious to either cells or virus have been con-
structed using inducible promoters (Massie et al., 1998;
Yoshida et al., 1997; Yoshida and Hamada, 1997), by
FIG. 5. Western analysis of FPRP Ig6/TM expression after transduc-
tion. 293 cells were transduced with Ad5dl327E1A-FPRP Ig6/TM–GFP
(lane labeled FPRP) or Ad5dl327E1A–GFP (lane labeled GFP) or trans-
fected with a plasmid encoding FPRP Ig6/TM–GFP under the control of
the CMV promoter (lane labeled Tfxn) as a positive control. Proteins
were metabolically labeled, immunoprecipitated using antibody
against GFP, and electrophoretically resolved. The locations of FPRP
Ig6/TM–GFP and GFP are indicated by lines on the left and the mobil-
ities of marker proteins are indicated in kDa on the right. The location
of the dye front is indicated by “df.” In the GFP lane, a band migrating
ahead of GFP is present and presumably represents a degradation
product of GFP.including a sequence element that inhibits gene expres-
sion and then deleting this element when growing largeamounts of virus as a transducing stock (Bilbao et al.,
1999) and by making 293 cells immune to the deleterious
functions of the transgene (Hedlund et al., 1999; Shinoura
et al., 1998). The data presented here demonstrate that
the adenovirus E1A promoter exhibits very little activity
during the early phase of infection of 293 cells and
therefore offers a simple means to construct adenovirus
transducing vectors that encode proteins deleterious to
growth of the virus. The use of the E1A promoter also
extends the available range of expression of the trans-
gene, an important consideration in cases where over-
expression of the transgene can lead to artifactual re-
sults.
The activities of the CMV, RSV, and E1A promoters
were examined using GFP as reporter (Figs. 3 and 4).
The half-life of enhanced GFP is approximately 26 h in
murine LA-9 cells (Corish and Tyler-Smith, 1999) and is
likely to be similar in 293 and HeLa cells. The stability of
GFP complicates analysis of promoter strength, but ki-
netic studies of GFP activity permit conclusions to be
drawn. Not surprisingly, the CMV promoter is the stron-
gest of the three promoters in both 293 and HeLa cells in
both transfection and transduction assays. The RSV pro-
moter exhibits activity similar to that of the CMV pro-
moter in transduced cells after the onset of replication,
but much less activity prior to replication of the template.
The increased activity of the RSV promoter after the
onset of viral DNA replication could reflect saturation of
the limiting transcription component(s) only at a relatively
high intracellular concentration of RSV promoters. How-
ever, the data suggest that in HeLa and 293 cells, the
RSV promoter functions as a late promoter similar to the
adenovirus major late promoter, which exhibits little ac-
tivity prior, and substantially increased activity subse-
quent, to the onset of viral DNA replication (Glenn and
Ricciardi, 1988; Shaw and Ziff, 1980; Thomas and
Mathews, 1980).
Since the RSV promoter exhibits little activity during
the early phase of infection in 293 cells, it is possible that
this promoter will prove useful in the construction of
transducing vectors encoding deleterious gene prod-
ucts. High-level expression of such gene products may
be better tolerated during the late phase of infection of
293 cells, when the physiology of the cells has been
dramatically altered due to adenovirus infection, than
during the early phase of infection. In support of this
argument, the use of the RSV promoter appeared to
permit, albeit inefficiently, the construction of a virus
encoding FPRP Ig6/TM–GFP.
The demonstration of the utility of the E1A promoter in
the construction and growth of adenovirus transducing
vectors and the power of the AdEasy system for the
construction of adenovirus transducing vectors led us to
construct a shuttle vector, pShuttleE1A, containing the
E1A promoter for use in the AdEasy system. The devel-
opment of shuttle vectors in which transgene expression
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(e.g., Wan et al., 2000) will increase the utility of the
AdEasy system, extending the range of cDNAs that can
be used to construct transducing virus as well as the
level of transgene expression.
MATERIALS AND METHODS
Plasmids
Adenovirus shuttle plasmids that contain the left end
of the adenovirus type 5 chromosome through the XhoI
site at bp 5788 were constructed. Promoterless plasmids
have the region between bp 358 and 3318 replaced by
polylinkers containing the following sites: BamHI, EcoRI,
KpnI, XbaI, HpaI, SalI, MluI, HindIII (pXC15#7) or HindIII,
MluI, SalI, HpaI, XbaI, KpnI, EcoRI, BamHI, BglII
(pXC15#18). Plasmids that contain the E1A promoter
have the region between bp 501 and 3318 replaced by
polylinkers containing the following sites: HindIII, MluI,
SalI, HpaI, XbaI, KpnI, EcoRI, BamHI, BglII (pXC15E1A#9)
or BglII, BamHI, EcoRI, KpnI, XbaI, HpaI, SalI, MluI, HindIII
(pXC15E1A#12). A plasmid containing the RSV promoter,
pXC15RSV, was constructed by cloning the RSV pro-
moter from the plasmid pRSV-EGFP (a generous gift
from R. Mahalingham, University of Colorado Health
Sciences Center) into pXC15#18. The resultant plas-
mid, pXC15RSV, contains the following unique sites in
the multiple cloning region: HindIII, EcoRI, SalI, KpnI,
and BamHI. To generate a shuttle vector containing
the E1A promoter (pShuttleE1A), the left end of the
viral chromosome through bp 501, which includes the
entire E1A promoter and the E1A cap site at bp 499
(Baker and Ziff, 1981), was PCR amplified from the
plasmid pXC15E1A#9 using the oligonucleotides 59-
CCTTAATTAACATCATCAATAATATACCTTATTTT-39 and
59-CCGGTACCAGTGGCCTCTTGAGGAACTC-39 and
cloned into the plasmid pShuttle that had been par-
tially digested with PacI in the presence of 40 mg/ml
ethidium bromide (Parker et al., 1977; O¨sterlund et al.,
1982) followed by complete digestion with KpnI. This
construction maintains the multiple cloning site from
pShuttle (He et al., 1998). Sequence analysis demon-
strated a G–A transition at position 337 that does not
affect the cis-acting packaging element (Schmid and
Hearing, 1997) and was therefore expected to be si-
lent. The remainder of the sequence is wild-type. The
CMV vector used was pACCMV#95 (a derivative of
pACCMV (Gomez-Foix et al., 1992), which has the
polylinker inverted; a generous gift from D. Reed,
Swiss Cancer Research Institute, Lausanne, Switzer-
land). The enhanced, red-shifted, humanized GFP
gene (Clontech) was cloned into the shuttle vectors to
yield pCMV–GFP, pE1A–GFP, and pRSV–GFP.
A cDNA encoding the FPRP Ig6/TM region (Orlicky,
1996; Orlicky and Nordeen, 1996) was cloned behind the
CMV promoter in the plasmid pAdTrackCMV (He et al.,1998) to generate the plasmid pAdTrackCMV-FPRP Ig6/
TM. The RSV promoter was cloned into the plasmid
pShuttle (He et al., 1998) to generate pShuttleRSV. A
cDNA encoding FPRP Ig6/TM as a fusion protein with
GFP was then introduced into pShuttleRSV to yield
pShuttleRSV-FPRP Ig6/TM–GFP. The FPRP Ig6/TM–GFP
cDNA was also cloned into the plasmids pXC15E1A#9
and pShuttleE1A to generate pXC15E1A-FPRP Ig6/TM–
GFP and pShuttleE1A-FPRP Ig6/TM–GFP, respectively.
Cells and viruses
293 (Graham et al., 1977) and HeLa cells were grown
at 37°C in the presence of 5% CO2 in DMEM supple-
mented with 10% bovine calf serum. HeLa suspension
cells were grown at 37°C in Joklik-modified minimal
essential medium for suspension cell growth (SMEM)
containing 7% horse serum.
Viruses were constructed, grown, and titered using
293 cells. Viruses used included Ad5dl310, which is phe-
notypically wild-type and contains a 27-bp deletion
within the E1A gene (Jones and Shenk, 1978), and
Ad5dl327Bstb-gal (Schaack et al., 1995) and Ad5dl327,
which were used in the construction of new viruses by
overlap recombination (Chinnadurai et al., 1979). Viruses
were purified by banding consecutively on step (1.25 and
1.4 g/cc) and isopycnic (1.35 g/cc) CsCl gradients and
dialyzed 33 1 h at 4°C against a buffer containing 10 mM
Tris–HCl, pH 8.0, 135 mM NaCl, 1 mM MgCl2, and 50%
glycerol and stored at 220°C. Particle titers were deter-
mined by absorbence at 260 nm, where 1 A260 unit was
considered equivalent to 1012 particles, and plaque titers
were determined using 293 cells. Particle titers were
approximately 100-fold higher than plaque titers for all of
the recombinant adenoviruses.
Construction of recombinant viruses
Ad5dl327Bstb-gal-TP (terminal protein) complex was
prepared by banding purified Ad5dl327Bstb-gal on a gra-
dient containing 2.8 M CsCl and 4 M guanidinium–HCl.
The gradient was fractionated by dripping and fractions
containing DNA were determined by agarose gel elec-
trophoresis. Positive fractions were combined and dia-
lyzed extensively vs 10 mM Tris–HCl, pH 8.0, 0.1 mM
EDTA. Ad5dl327Bstb-gal-TP was digested with BstBI,
which cleaves immediately 39 of the LacZ coding se-
quence (Schaack et al., 1995), and was used with cal-
cium phosphate precipitation (Jordan et al., 1996), to
cotransfect 293 cells with plasmids encoding GFP under
the control of the CMV and E1A promoters. Transfected
plates were incubated for 7 days. Viruses were released
by freezing and thawing the cells and were plaque-
purified in 293 cells. Plates were stained with X-gal to
indicate background plaques resulting from the parental
virus and fluorescent plaques were picked. Plaques
were expanded in 293 cells and purified by sequential
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ing viruses are schematically represented in Fig. 2.
Construction of viruses encoding FPRP Ig6/TM
The AdEasy system (He et al., 1998) was used in
attempts to construct viruses encoding the FPRP Ig6/TM
region under the control of the CMV, RSV, and E1A
promoters. To generate recombinant plasmids, we used
a modification of the AdEasy system that we previously
found to increase efficiency (Orlicky and Schaack, 2001).
Twenty nanograms of each plasmid linearized by diges-
tion with PmeI was used to electroporate Escherichia
coli strain BJ5183 that had previously been transformed
with the plasmid pAdEasy1 (E. coli BJ5183 (pAdEasy1)).
Recombinant pAdEasy1 plasmids containing the cDNA
of interest were digested with PacI prior to introduction
into 293 cells by calcium phosphate precipitation to gen-
erate viruses. Attempts were also made to generate
transducing adenoviruses encoding FPRP Ig6/TM–GFP
under the control of the CMV and E1A promoters using
overlap recombination by cotransfection of 293 cells with
BstBI-digested Ad5dl327Bstb-gal-TP complex. Finally, at-
tempts were made to construct a transducing virus en-
coding FPRP Ig6/TM under the control of the CMV pro-
moter through ligation, a method that we have found to
be extremely efficient (Fagan et al., 1999; Schaack et al.,
unpublished results). For this purpose, pCMV-FPRP
Ig6/TM was modified by introduction of a BstBI site
immediately downstream of the FPRP Ig6/TM coding
sequence. The plasmid was digested with FspI, which
generates a blunt-ended site within the b-lactamase
gene, thereby inhibiting recircularization, and BstBI prior
to ligation with BstBI-digested Ad5dl327Bstb-gal-TP and
transfection of 293 cells. Attempts to isolate plaques
were as outlined above for isolation of viruses encoding
GFP.
RNA isolation and analysis
Cytoplasmic RNA was isolated by lysing cells in 10
mM Tris–HCl, pH 8.0, 10 mM NaCl, 3 mM MgCl2, 0.5% v/v
NP-40, removing nuclei by centrifugation, and deprotein-
izing by digesting with 100 mg/ml proteinase K at 37°C
for 60 min in the presence of 0.5% SDS followed by
phenol extraction and ethanol precipitation. E1A RNA
was analyzed by RNase protection (Melton et al., 1984)
using 5 mg of total cytoplasmic RNA and labeled anti-
sense E1A probe in sufficient excess to saturate binding.
Analysis of promoter activity: Transfections and
infections
293 and HeLa cells in 60-mm plates at approximately
70% of confluence were transfected with 5 mg of the
different plasmids using calcium phosphate precipitation
for 1 min prior to overlaying of the precipitate on the cells
(Jordan et al., 1996). Five to 8 h later, the cells were fedfresh medium. Cells were transduced at an m.o.i. of 20
PFU/cell. After the times indicated, cells were washed
with PBS and harvested by scraping. The extracts were
rapidly frozen and thawed three times followed by vigor-
ous vortexing. Debris was pelleted by centrifugation for 1
min at 8000 g at 4°C. GFP activity was determined
fluorometrically with excitation at 490 nm and emission
at 520 nm.
Immunoprecipitations
293 cells were infected with the test viruses at an
m.o.i. of approximately 10 PFU/cell. Twenty-four hours
later, the medium was replaced by methionine-, cys-
teine-, and serum-free medium. One hour later, 100 mCi
[35S]methionine and [35S]cysteine (Translabel, Amersham
Life Science) was added and incubation continued for
1 h. The medium was replaced with normal medium for
an additional 1 h. The medium was then removed and
the cells were lysed in phosphate-buffered saline (PBS)
containing 1% Brij 97 and protease inhibitors phenyl-
methylsulfonyl fluoride (2 mM), aprotinin (250 mg/ml),
leupeptin (250 mg/ml), antipain (25 mg/ml), and chymo-
statin (25 mg/ml) by rocking the plates for 15 min on ice
followed by tumbling in tubes for 1 h at 4°C. The insol-
uble material was pelleted by centrifugation at 8000 g for
15 min at 4°C and the supernatant was transferred to a
new tube. Monoclonal antibody against GFP (Clontech)
was added and the tube tumbled overnight at 4°C. Pro-
tein A–Sepharose (20 ml of a 1:1 slurry in PBS; Sigma)
was added and the tube tumbled an additional 2 h. The
protein A–Sepharose was gently pelleted. The pellet was
washed 3 times with PBS containing 1% Brij 97 and
protease inhibitors and then washed 3 times with PBS,
all at 4°C. The pellet was resuspended in 0.14 M Tris–
HCl, 12% sodium dodecyl sulfate, 10% b-mercaptoetha-
nol, 0.001% w/v bromophenol blue, pH 6.8, and heated in
a boiling water bath for 3 min, and the soluble material
was electrophoretically resolved on a 10% polyacryl-
amide (29:1 acrylamide:bisacrylamide) gel. The gel was
fixed for 1 h in 20% methanol, 10% acetic acid, washed for
1 h in water, soaked for 1 h in 1 M sodium salicylate, and
dried at 60°C. Radioactively labeled proteins were visu-
alized by exposure to Kodak X-OMAT AR film.
ACKNOWLEDGMENTS
This work was supported by NIH Grant HL58344 and a grant from the
Cancer League of Colorado to J.S., Grant CWGS-44-97 from the Amer-
ican Heart Association to D.J.O., and NIH Grant NS01741 to R.L.S. We
thank L.-J. Su for constructing left end plasmids containing polylinkers,
T. Vincent for construction of pE1A-FPRP Ig6/TM, M. Glode for support
provided by the UCHSC Gene Therapy Program, and G. Clayton for
helpful discussions.
REFERENCES
Alwine, J. C. (1985). Transient gene expression control: Effects of trans-
fected DNA stability and trans-activation by viral early proteins. Mol.
Cell. Biol. 5, 1034–1042.
108 SCHAACK ET AL.Ambriovic, A., Adam, M., Monteil, M., Paulin, D., and Eloit, M. (1997).
Efficacy of replication-defective adenovirus-vectored vaccines: Pro-
tection following intramuscular injection is linked to promoter effi-
ciency in muscle representative cells. Virology 238, 327–335.
Baker, C. C., and Ziff, E. B. (1981). Promoters and heterogeneous 59
termini of the messenger RNAs of adenovirus serotype 2. J. Mol. Biol.
149, 189–221.
Berk, A. J., Lee, F., Harrison, T. F., Williams, J. F., and Sharp, P. A. (1979).
Pre-early adenovirus 5 gene product regulates synthesis of early
viral messenger RNAs. Cell 17, 935–944.
Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. (1994). An efficient
and flexible system for construction of adenovirus vectors with in-
sertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci.
USA 91, 8802–8806.
Bilbao, G., Zhang, H., Contreras, J. L., Zhou, T., Feng, M., Saito, I.,
Mountz, J. D., and Curiel, D. T. (1999). Construction of a recombinant
adenovirus vector encoding Fas ligand with a CRE/Loxp inducible
system. Transplant Proc. 31, 792–793.
Castro, M. G., Goya, R. G., Sosa, Y. E., Rowe, J., Larregina, A., Morelli, A.,
and Lowenstein, P. R. (1997). Expression of transgenes in normal and
neoplastic anterior pituitary cells using recombinant adenoviruses:
Long term expression, cell cycle dependency, and effects on hor-
mone secretion. Endocrinology 138, 2184–2194.
Chartier, C., Degryse, E., Gantzer, M., Dieterle, A., Pavirani, A., and
Mehtali, M. (1996). Efficient generation of recombinant adenovirus
vectors by homologous recombination in Escherichia coli. J. Virol. 70,
4805–4810.
Chinnadurai, G., Chinnadurai, S., and Brusca, J. (1979). Physical map-
ping of a large-plaque mutation of adenovirus type 2. J. Virol. 32,
623–628.
Corish, P., and Tyler-Smith, C. (1999). Attenuation of green fluorescent
protein half-life in mammalian cells. Protein Eng. 12, 1035–1040.
Crouzet, J., Naudin, L., Orsini, C., Vigne, E., Ferrero, L., Le Roux, A.,
Benoit, P., Latta, M., Torrent, C., Branellec, D., Denefle, P., Mayaux,
J. F., Perricaudet, M., and Yeh, P. (1997). Recombinational construc-
tion in Escherichia coli of infectious adenoviral genomes. Proc. Natl.
Acad. Sci. USA 94, 1414–1419.
Elshami, A. A., Cook, J. W., Amin, K. M., Choi, H., Park, J. Y., Coonrod, L.,
Sun, J., Molnar-Kimber, K., Wilson, J. M., Kaiser, L. R., and Albelda,
S. M. (1997). The effect of promoter strength in adenoviral vectors
containing herpes simplex virus thymidine kinase on cancer gene
therapy in vitro and in vivo. Can. Gene Ther. 4, 213–221.
Fagan, K. A., Rich, T. C., Tolman, S., Schaack, J., Karpen, J. W., and
Cooper, D. M. F. (1999). Adenovirus-mediated expression of an ol-
factory cyclic nucleotide-gated channel regulates the endogenous
Ca21-inhibitable adenylyl cyclase in C6–2B glioma cells. J. Biol.
Chem. 274, 12445–12453.
Fukuchi, K., Hearn, M. G., Deeb, S. S., Smith, A. C., Dang, N., Miyazaki,
J., Bothwell, M., and Martin, G. M. (1994). Activity assays of nine
heterogeneous promoters in neural and other cultured cells. In Vitro
Cell. Devel. Biol. Anim. 30A, 300–305.
Glenn, G. M., and Ricciardi, R. P. (1988). Detailed kinetics of adenovirus
type-5 steady-state transcripts during early infection. Virus Res. 9,
73–91.
Gomez-Foix, A. M., Coats, W. S., Baque, S., Alam, T., Gerard, R. D., and
Newgard, C. B. (1992). Adenovirus-mediated transfer of the muscle
glycogen phosphorylase gene into hepatocytes confers altered reg-
ulation of glycogen metabolism. J. Biol. Chem. 267, 25129–25134.
Gorman, C. M., Gies, D., McCray, G., and Huang, M. (1989). The human
cytomegalovirus major immediate early promoter can be trans-acti-
vated by adenovirus early proteins. Virology 171, 377–385.
Graham, F. L., Rudy, J., and Brinkley, P. (1989). Infectious circular DNA of
human adenovirus type 5: Regeneration of viral DNA termini from
molecules lacking terminal sequences. EMBO J. 88, 2077–2085.
Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977). Charac-
teristics of a human cell line transformed by DNA from human
adenovirus type 5. J. Gen. Virol. 36, 59–72.Guo, Z. S., Wang, L. H., Eisensmith, R. C., and Woo, S. L. (1996).
Evaluation of promoter strength for hepatic gene expression in vivo
following adenovirus-mediated gene transfer. Gene Ther. 3, 802–810.
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phipps, M. L.
(1997). Construction of adenovirus vectors through Cre–lox recom-
bination. J. Virol. 71, 1842–1849.
Hashimoto, M., Aruga, J., Hosoya, Y., Kanegae, Y., Saito, I., and Miko-
shiba, K. (1996). A neural cell-type-specific expression system using
recombinant adenovirus vectors. Hum. Gene Ther. 7, 149–158.
He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein,
B. (1998). A simplified system for generating recombinant adenovi-
ruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514.
Hearing, P., and Shenk, T. (1985). Sequence-independent autoregula-
tion of the adenovirus type 5 E1A transcription unit. Mol. Cell. Biol. 5,
3214–3221.
Hedlund, T. E., Schaack, J., Meech, S. J., Miller, G. J., Kraft, A. S., and
Duke, R. C. (1999). Adenovirus-mediated expression of Fas ligand in
human prostate cancer cell lines. Cell Death Differ. 6, 175–182.
Imler, J. L., Dupuit, F., Chartier, C., Accart, N., Dieterle, A., Schultz, H.,
Puchelle, E., and Pavirani, A. (1996). Targeting cell-specific gene
expression with an adenovirus vector containing the lacZ gene under
the control of the CFTR promoter. Gene Ther. 3, 49–58.
Jiang, C., O’Connor, S. P., Armentano, D., Berthelette, P. B., Schiavi, S. C.,
Jefferson, D. M., Smith, A. E., Wadsworth, S. C., and Cheng, S. H.
(1996). Ability of adenovirus vectors containing different CFTR tran-
scriptional cassettes to correct ion transport defects in CF cells.
Am. J. Physy. 271(4 Pt 1), L5275–5237.
Jones, N., and Shenk, T. (1978). Isolation of deletion and substitution
mutants of adenovirus type 5. Cell 13, 181–188.
Jones, N., and Shenk, T. (1979a). An adenovirus type 5 early gene
function regulates expression of other early viral genes. Proc. Natl.
Acad. Sci. USA 76, 3665–3669.
Jones, N., and Shenk, T. (1979b). Isolation of adenovirus type 5 host
range deletion mutants defective for transformation of rat embryo
cells. Cell 17, 683–689.
Jordan, M., Schallhorn, A., and Wurm, F. M. (1996). Transfecting mam-
malian cells: Optimization of critical parameters affecting calcium-
phosphate precipitate formation. Nucleic Acids Res. 24, 596–601.
Ketner, G., Spencer, F., Tugendreich, S., Connelly, C., and Hieter, P.
(1994). Efficient manipulation of the human adenovirus genome as
infectious yeast artificial chromosome clone. Proc. Natl. Acad. Sci.
USA 91, 6186–6190.
Larregina, A. T., Morelli, A. E., Dewey, R. A., Castro, M. G., Fontana, A.,
and Lowenstein, P. R. (1998). FasL induces Fas/Apo1-mediated
apoptosis in human embryonic kidney 293 cells routinely used to
generate E1-deleted adenoviral vectors. Gene Ther. 5, 563–568.
Massie, B., Couture, F., Lamoureux, L., Mosser, D. D., Guilbault, C.,
Jolicoeur, P., Belanger, F., and Langelier, Y. (1998). Inducible overex-
pression of a toxic protein by an adenovirus vector with a tetracy-
cline-regulatable expression cassette. J. Virol. 72, 2289–2296.
Melton, D. A., Kreig, P. A., Rebagliate, M. R., Maniatis, T., Zinn, K., and
Green, M. R. (1984). Efficient in vitro synthesis of biologically active
RNA and RNA hybridization probes from plasmids containing a
bacteriophage SP6 promoter. Nucleic Acids Res. 12, 7035–7056.
Mitani, K., Graham, F. L., Caskey, C. T., and Kochanek, S. (1995). Rescue,
propagation, and partial purification of a helper virus-dependent
adenovirus vector. Proc. Natl. Acad. Sci. USA 92, 3854–3858.
Mizuguchi, H., and Kay, M. A. (1998). Efficient construction of a recom-
binant adenovirus vector by an improved in vitro ligation method.
Hum. Gene Ther. 20, 2577–2583.
Orlicky, D. J. (1996). Negative regulatory activity of a prostaglandin F2a
receptor associated protein. Prostaglandins, Leukotrienes Essential
Fatty Acids 54, 247–254.
Orlicky, D. J., Lieber, J. G., Morin, C. L., and Evans, R. M. (1998).
Synthesis and accumulation of a receptor regulatory protein associ-
ated with lipid droplet accumulation in 3T3–L1 cells. J. Lipid Res. 39,
1152–1161.
109PROMOTER ACTIVITY IN ADENOVIRUS VECTORSOrlicky, D. J., and Nordeen, S. K. (1996). Cloning, sequencing and
proposed structure for a prostaglandin F2a receptor regulatory
protein. Prostaglandins, Leukotrienes Essential Fatty Acids 55,
261–268.
Orlicky, D. J., and Schaack, J. (2001). Adenovirus transduction of 3T3–L1
cells. J. Lipid Res. 42, 910–915.
O¨sterlund, M., Luthman, H., Nilsson, S. V., and Magnusson, G. (1982).
Ethidium-bromide-inhibited restriction endonucleases cleave one
strand of circular DNA. Gene 20, 121–125.
Parker, R. C., Watson, R. M., and Vinograd, J. (1977). Mapping of closed
circular DNAs by cleavage restriction endonucleases and calibration
by agarose gel electrophoresis. Proc. Natl. Acad. Sci. USA 74, 851–
855.
Sallenave, J. M., Xing, Z., Simpson, A. J., Graham, F. L., and Gauldie, J.
(1998). Adenovirus-mediated expression of an elastase-specific in-
hibitor (elafin): A comparison of different promoters. Gene Ther. 5,
352–360.
Schaack, J., Langer, S. J., and Guo, X. (1995). Efficient selection of
recombinant adenoviruses using vectors that express b-galactosi-
dase. J. Virol. 69, 3920–3923.
Schmid, S. I., and Hearing, P. (1997). Bipartite structure and functional
independence of adenovirus type 5 packaging elements. J. Virol. 71,
3375–3384.
Shaw, A. R., and Ziff, E. B. (1980). Transcripts from the adenovirus-2
major late promoter yield a single early family of 39 coterminal
mRNAs and five late families. Cell 22, 905–916.
Shenk, T., Jones, N., Colby, W., and Fowlkes, D. (1979). Functional
analysis of adenovirus type 5 host range deletion mutants defective
for transformation of rat embryo cells. Cold Spring Harbor Symp.
Quant. Biol. 44, 367–375.Shinoura, N., Ohashi, M., Yoshida, Y., Asai, A., Kirino, T., Saito, I., and
Hamada, H. (1998). Construction, propagation, and titer estimation ofrecombinant adenoviruses carrying proapoptotic genes. Hum. Gene
Ther. 9, 2683–2689.
Smith, D. H., Kegler, D. M., and Ziff, E. B. (1985). Vector expression of
adenovirus type 5 E1a proteins: Evidence for E1a autoregulation.
Mol. Cell. Biol. 5, 2684–2696.
Smith, R. L., Traul, D. L., Schaack, J., Clayton, G. H., Staley, K. J., and
Wilcox, C. (2000). Characterization of promoter function and cell-type
specific expression from viral vectors in the nervous system. J. Virol.
74, 11254–11261.
Staley, K., Smith, R., Schaack, J., Wilcox, C., and Jentsch, T. (1996).
Alteration of GABA-A receptor function following gene transfer of the
ClC-2 chloride channel. Neuron 17, 543–551.
Varley, A. W., Coulthard, M. G., Meidell, R. S., Gerard, R. D., and
Munford, R. S. (1995). Inflammation-induced recombinant protein
expression in vivo using promoters from acute-phase protein genes.
Proc. Natl. Acad. Sci. USA 92, 5346–5350.
Wan, Y. Y., Leon, R. P., Marks, R., Cham, C. M., Schaack, J., Gajewski,
T. F., and DeGregori, J. (2000). Transgenic expression of the cox-
sackie/adenovirus receptor (CAR) enables adenoviral mediated
gene delivery in naive T cells. Proc. Natl. Acad. Sci. USA 97, 13784–
13789.
Xu, Z. Z., Krougliak, V., Prevec, L., Graham, F. L., and Both, G. W. (1995).
Investigation of promoter function in human and animal cells infected
with human recombinant adenovirus expressing rotavirus antigen
VP7sc. J. Gen. Virol. 76, 1971–1980.
Yoshida, Y., Emi, N., and Hamada, H. (1997). VSV-G-pseudotyped retro-
viral packaging through adenovirus-mediated inducible gene expres-
sion. Biochem. Biophys. Res. Commun. 232, 379–382.
Yoshida, Y., and Hamada, H. (1997). Adenovirus-mediated inducible
gene expression through tetracycline-controllable transactivator with
nuclear localization signal. Biochem. Biophys. Res. Commun. 230,
426–430.
